The FDA stacked a panel with peptide sellers. Guess what it just greenlit

On Peptides, FDA Staff Scientists At Odds With Advisory Panel

Though FDA would normally follow a panel’s advice to move ahead with compounded peptides, it’s unclear how it will act, because FDA staff are opposed to easing access.